Kinetic analysis of steroid 5 alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue : evidence for type I isozyme activity in the human prostate by Span, P.N. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/24208
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Pergamon
J. Steroid Biochem. Molec. Biol. Vol. 57, No. 1/2, pp. 103-108, 1996
Copyright © 1996 Elsevier Science Ltd. All rights reserved
0960-0760(95)00167-0 Printed in Great Britain
0960-0760/96 $15.00 + 0.00
Kinetic Analysis of Steroid 5a-Reductase 
Activity at Neutral pH in Benign Prostatic 
Hyperplastic Tissue: Evidence for Type 
Isozyme Activity in the Human Prostate
P. N. Span,1* Th. J. Benraad,2 C. G. J. Sweep2 and A. G. H. Smals1
d ep a r tm en t of Medicine , Division of Endocrinology and 2Department o f Experimental and Chemical Endocrinology¡
University Hospital Nijmegen, Nijmegen , The Netherlands
In human benign prostatic hyperplastic (BPH) tissue homogenates 5a-reduction of testosterone was 
examined at neutral pH. As Lineweaver-Burk and Eadie-Scatchard plots of estimated initial 
velocities against a wide range of substrate concentrations of 2 nM to 3.2 fiM were non-linear, the 
existence of two 5a-reductase isozymes in this tissue was surmised. Indeed, enzyme parameters at 
pH 7.0 suggested the presence of two isozymes with affinity constants of 1995 and 11.8 nM, 
characteristic of the well established human steroid 5a-reductase isozymes type I and II, respect­
ively. The physiological roles of these isozyme activities remain puzzling. The specific activities, Fmax, 
of these subtypes indicated an approx. 6-fold higher maximum velocity of type I than of type II 
5a-reductase in the human hyperplastic prostate at this pH. In contrast, the efficiency ratios, 
VmaJ K m, demonstrated that the type II isozyme had a nearly 27 times higher potential in vivo  activity 
than the type I isozyme, and is therefore most probably quantitatively responsible for dihydrotestos­
terone formation at physiological testosterone levels in this tissue at neutral pH. This is the first full
paper on type I 5a-reductase activity in human BPH tissue. Copyright © 1996 Elsevier Science Ltd.
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INTRODUCTION I], one might assume that the human prostate indeed
Steroid 5a-reductase (E.C. 1.3.99.5) is a NADPH-de- contains both of these isozymes.
pendent enzyme capable of 5a-reducing a number of Prostatic 5a-reductase type II mRNA, -protein and
steroids with a 4,5 double bond and a 3-oxo group, -activity have been detected using cDNA probes
including glucocorticoids, progestogens, mineralcorti- [9,10], immunoblotting and immunocytochemistry
coids, androgens [1] and non-androgens such as the [10- 12], and pH profiles of 5a-reductase activity
pheromone precursor 4,16-androstadien-3-one [2,3]. [1, 13], respectively. In patients with 5a-reductase type
The 5a-reduction product of testosterone (T), dihy- II deficiency (male pseudohermaphroditism) prostate
drotestosterone (DHT), has been implicated in the development is impaired, indicating the importance of
pathogenesis of benign prostatic hyperplasia (BPH) [4]. this 5a-reductase isozyme for the growth and develop-
Earlier studies on the 5a-reductase enzyme charac- ment of the human prostate [14, 15]. It is therefore
teristics in prostatic epithelium and stroma revealed a intelligible that a specific type II isozyme inhibitor,
difference in affinity constants, which might indicate finasteride, has been developed for treatment of benign
the existence of two isozymes in the human prostate prostatic hyperplasia.
[5-8]. As it is now well established that there are two 
human 5a-reductase isozymes, i.e. type I and type II, 
with distinct pH-optima, tissue distribution, affinity
Data concerning the presence of the type I 5a- 
reductase in human prostate, however, are conflicting; 
the first human 5a-reductase cDNA was derived from
constants and sensitivity to inhibitors [as reviewed in prostatic tissue [13,16] and was shown to code for the
____________________________________ _ _ _ _ _ _  tyPe Ï isozyme. Using cDNA probes, mRNA for the
type I 5a-reductase has been found in the human 
prostate [9], whereas other investigators failed to
■^Correspondence to P* N. Span.
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demonstrate type I 5a-reductase mRNA in this tissue 
[10]. Furthermore, immunoblotting studies using 
specific antibodies against the 5a-reductase protein 
denies type I immunoreactivity [10312]. On the other 
hand, apparent affinity constants for 5a-reductase 
found in human prostatic tissues are consistent with 
type I activity [17] and preliminary data have been 
published in abstract form indicating both type I and 
type II 5a-reductase activity in this tissue [18].
There is growing evidence that both 5a-reductase 
isozymes operate at neutral pH [19]. By incubating 
homogenates of rat prostate and epididymis with a wide 
range of substrate concentrations, we were recently 
able to measure both rat isozymes simultaneously [20]. 
In the present study we applied the same procedure 
to human BPH homogenates. A careful analysis of 5a- 
reductase activity at pH 7.0 showed non-linear 
Lineweaver-Burk and Eadie—Scatchard [21] plots of 
initial velocity against substrate concentration. This 
could be adequately explained by the presence of two 
isozymes in BPH tissue. The kinetic characteristics of 
these isozymes were in concordance with those of the 
well established human steroid 5a-reductase type I and 
II isozymes. Both the type I and type II isozyme 
specific activities and potential in vivo  activities were 
determined.
MATERIALS A N D  METHODS
Materials
[1,236,7~3H]T (3.74 TBq/mmol) and [la,2a(n)- 
3H]-17/?-hydroxy-5a-androstan-3-one (DHT)
(2.00 TBq/mmol) were purchased from Amer sham 
(Amersham, U.K.). [9,ll-3H]5a~androstane-3a,17ß- 
diol (1.48 TBq/mmol) was obtained from Du Pont- 
New England Nuclear (Boston, MA). All radiolabelled 
steroids were purified by high performance liquid 
chromatography (HPLC, see below) before use. Non­
labelled T was purchased from Steraloids (Wilton3 
NH). Diethylether (p.a.)3 n -hexane (LiChrosolv) and 
2-propanol (LiChrosolv) were purchased from Merck 
(Darmstadt, FRG). All other chemicals used were of 
analytical grade.
Protein levels were determined by a modification of 
the method of Lowry et al. [22] against a standard 
bovine serum albumin (OHRD 20/21, Hoechst- 
Behring, Marburg, Germany). The assay was modified 
for microtiter-plates and had a sensitivity of 25 ¡x g per 
well.
Buffers
Homogenization buffer consisted of 20 mM phos­
phate (Merck), 1 mM monothioglycerol and 0.25 M 
sucrose (Merck), pH 7.0. T he incubation buffer con­
sisted of 200 mM Tris (2-amino-2-hydroxymethyl- 
propane-l,3-diol, Merck) and citric acid monohydrate 
(Merck), pH 4 .5-8.0 or pH 7.0, and 2mM NADPH  
tetrasodium salt (Merck).
Tissue preparation
Human benign prostatic hyperplastic tissues were 
obtained from 15 different patients, age 53-69 y3 un­
dergoing transurethral resection. Prostatic tissue chips 
were placed in liquid nitrogen for transport to the 
laboratory. Aliquots of each specimen were sent to the 
Department of Pathology for histological confirmation 
of BPH. Tissues were kept at — 80°C or processed 
immediately. All subsequent procedures were per­
formed on ice. Tissues (9.3 g total w/w) were pooled, 
thawed, and minced with razor blades into small pieces. 
Minced tissue was homogenized in ice-cold homogen­
ization buffer with a 7 ml Dounce tissue grinder 
(Kontes Glass Co., Vineland, NJ) with a loose and a 
tight fitting pestle. The homogenate was filtered twice 
through nylon netting of 50 and 140 mesh respectively 
to remove cell debris. By this procedure—without 
centrifugation—a full homogenate with nuclei and cy­
tosol is obtained. The pooled BPH homogenate was 
diluted with homogenization buffer to 5.4 mg pro­
tein/ml.
5a-reductase assay
Radiolabelled T in ethanol was brought to final 
concentration (2 nM-3.2 ¿¿M) by isotopie dilution with 
non-labelled steroid in Pyrex culture tubes (borosili- 
cate glass, 12 x 75 mm, Coming Inc., Corning, NY), 
Ethanol was evaporated under a mild nitrogen stream 
at room temperature. Incubation buffer (800 fd) was 
added and the tubes were put into a shaking water bath 
at 37°C at least 10 min before the start of the incubation 
to ensure the substrate was dissolved (97%). A tube 
with the homogenate (50-100 ¡x\) and the appropriate 
amount of cofactor (NADPH, 2 mM final concen­
tration) was diluted to 200 ¿^1 with 100-150 ¡x\ incu­
bation buffer and kept on ice. The incubation was 
started by adding 200 jx 1 of the homogenate and cofac­
tor mixture to the pre-heated tubes with substrate. 
After 10-30 min the incubation was terminated by 
adding 100 ¡ i l  of 3 M NaOH. This 5a-reductase assay 
protocol was optimized for rat tissues (prostate and 
epididymis) in an earlier paper [23]. The assay was 
evaluated for BPH tissues, and was checked for linear­
ity in time and protein concentration. T  metabolism 
was not allowed to exceed 15% by varying enzyme 
concentration and incubation time. To extract metab­
olites, 4 ml of ice-cold diethylether was added, and the 
tubes were capped and shaken. The water phase was 
frozen in an alcohol bath with dry-ice, the organic 
phase decanted and evaporated under nitrogen. Metab­
olites were dissolved in 100/d hexane for HPLC.
H P L C
Metabolized steroids were separated on a Hibar 
LiChrosorb Diol-column (length 250 mm, 5 /¿m, 
Merck), equipped with a guard column (Resolve Silica, 
Waters Corp.3 Milford, MA). The HPLC-system
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included a Waters 610 Fluid Unit* a Waters 600E initial burst in the time course of the 5a-reduction of 
System Controller and a Waters U 6K injector. The T* reported by others in BPH particulate fractions [26] 
isocratic flow of the mobile phase (hexane-propanol and by us in rat epididymis and prostate [23]* was also
96:4, v/v) was 1.5ml/min at a pressure of 680 psi. countered with the applied protocol in the present
study. This procedure led to a linear time-course 
during the incubation period for at least 30 min* allow-
Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radio-chromatography detector 
(Packard-Canberra Benelux, Tilburg., The Nether- ing for the estimation of initial velocities. Finally* 
lands) with a 500 fi\ cell and a liquid scintillation flow 10-100¿d of the diluted homogenate (0.054-0.54 mg
protein) was incubated under the established con­
ditions mentioned in the Materials and Methods sec-
of 1.5ml/min (Aqua-Luma, L,umac-LSC, Olen, Bel­
gium). The counting efficiency for tritium was 47%.
The percentage formation of D H T  and 5a-androstane- tion. The velocities were linear for the entire protein 
3a//?,17/?-diol was used to estimate 5a-reductase ac- concentration range tested (results not shown).
tivity. Overall experimental recoveries for T, D H T  and 
5a-androstane-3a//?,17/?~diol were 90-93%.
Calculation o f enzyme characteristics
p H  optim um
A pH profile of enzyme activity was made over the 
pH range 4.5-8.0 using 4 substrate concentrations
Velocities were plotted against T  concentration* and (Fig. 1). For purpose of comparison* the initial velocity
at the optimum pH is arbitrarily set at 100% for each 
of the T  concentrations. At T concentrations of 100*
K m m^ax were calculated using a non-linear re­
gression procedure based on a Michaelis-Menten
equation for two isozyme activities. A double reciprocal 2OO and 1000 nM, the optimum of initial velocity was
plot of the obtained estimated initial velocities against 
substrate concentration was used. This Lineweaver- 
Burk plot appeared to be non-linear at high T  concen­
trations. Furthermore* an Eadie-Scatchard plot of isozym e activities at neutra l p H
found at pH 5.5. However* at a lower T  concentration 
of 10 nM* the optimum was at pH 6.0.
velocity over substrate concentration (V/S) against 
velocity (V) was used for a more even weighting of 
points [21]. This plot was clearly non-linear and indi­
cated the presence of isozyme activities. Two 5a- 
reductase activities with different Fmaji and K m could be 
calculated using the same non-linear regression pro­
cedure with fitting to least squares. For the use of the 
V maJ K m ratio as an index of potential enzyme activity 
one has to consider that endogenous T  concentrations 
are much lower than the K m of either 5a-reductase 
subtype [5]. Therefore applying /<m» [ S ]  in the 
Michaelis-Menten equation gives:
V
r  max*r p i
i r l S ] '
At pH 7.0 the initial velocities were estimated over 
a wide concentration range of 2 n M -3 .2 /¿M T  
[Fig. 2(A)], As the double reciprocal plot of these data 
was non-linear at high T  concentrations [Fig. 2(B)], a 
non-linear fit to least squares was used and the enzyme 
parameters of two 5a-reductase isozymes could be 
calculated. An Eadie-Scatchard plot of V/S against V 
was used for a more even weighting of points [Fig. 2(C)] 
and was more clearly non-linear. One subtype was 
calculated with a Fmax of 50.8 fmol/(min-mg protein) 
and a K m of 11.8nM* which is characteristic of the 
established type II isozyme at this pH. The other 
subtype could be defined as having a ofmax
m
So* at physiological T  concentrations, the enzyme 
reaction velocity is proportional to V maJ K m.
% of maximum activity
120
100
RESULTS
Validity o f the 5 a-reducíase assay
In this study we investigated the 5a-reductase 
characteristics in human benign prostatic hyperplastic 
tissue homogenates. The 5a-reductase assay we applied 
was optimized and its validity checked in rat tissues as 
reported in an earlier paper [23]. The validity of this 
protocol was confirmed for the present study in BPH 
homogenates. In the absence of cofactor, the enzyme 
was unstable at 37°C. This deterioration could be 
countered by adding cofactor during the preincubation. 
With 2 mM NADPH* the enzyme activity was stable 
for at least 30 min at 37°C. This stabilization of enzyme 
activity by preincubating with cofactor has been re­
ported earlier by others [24* 25]. Furthermore* the
pH
Fig. 1. pH-Profiles of 5a-reductase activity a t  2m M  NADPH 
and with (4 )1 0  nM, (A) 100 nM, (■ ) 200 nM and ( • )  1000 nM 
T  as substrate. The optim um  pH for 5a-reductase activity in 
hum an BPH  tissue depends on the substrate  concentration 
chosen. For purposes of com parison a t  each concentration 
the op tim um  activity was a rb itra rily  set at 100%.
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313.1 fmol/(min-mg protein) and a K m of 1995nM,
corresponding to K m values reported for the type I
isozyme. The efficiency ratio V mJ K m of the alleged
6type I isozyme was 0.16-10“ l/(min-mg protein), 
whereas the type II isozyme had an approx. 27-fold 
higher V mJ K m ratio of 4.30- 10~6l/(min-mg protein),
S(mM)
For purpose of comparison, the Kmax and the V mJ K m 
ratios of both isozymes at pH 7.0 are shown in Fig. 3. 
Although the Kmax of the type I 5a-reductase isozyme 
was 6.2-fold higher than that of the type II, it yet 
appeared that the potential in vivo  activity at pH 7.0 is 
mainly attributable to the type II isozyme, as evidenced 
by its much higher V müJ K m ratio.
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DISCU SSIO N
In this study we investigated the 5a -reductase 
characteristics of human benign prostatic hyperplastic 
tissue homogenates. In a previous paper [23] we de­
scribed deterioration of enzyme activity at both pH 5.0 
and at pH 7.0 in the absence of cofactor at 37°C in rat 
prostate and rat epididymis. The enzyme activity was 
stable for 30 min at 37°C with 2nM  NADPH. This 
also applied to 5a-reductase activities in BPH hom­
ogenates described in the present paper. The initial 
burst in the time-course of 5a-reductase activity 
[23, 26] was not present with the protocol applied in 
500 this study. Furthermore, the activity was linear over 
the whole protein concentration range tested. There­
fore., we conclude that the values we established here 
are reasonable estimates of initial velocity.
We established the pH-optimum for 5a-reductase 
activity in BPH homogenates. This pH-optimum of 
5a-reductase activity in human prostate has been re­
ported to vary from as low as pH 5.0 [13], to pH 5.5 
[26] or even 7.0 [8,17]. In this study we measured the 
pH dependency of 5a-reductase activity at substrate 
concentrations ranging from 10 to 1000 nM T. At the
0.05 0.10 0.15 0.20 
V (pmol/(min*mg protein))
0.25
Fig. 2. (A) Estimated initial velocities (V) of 5a-reductase 
activity in human BPH tissue homogenates at pH 7.0 with 
2 mM NADPH and with 2nM to 3.2 jiM T as substrate (S). 
Values are given as mean ± S.D. of three duplicate assays 
carried out on different days. (B) A double reciprocal plot of 
the data reported in A is non-linear a t high T concentrations. 
(C) An Eadie-Scatchard plot of the  data  reported in A of 
estimated initial velocities over substrate concentration 
(V/S) against velocity (V) in hum an B PH  tissue homogenates 
at pH 7.0. This plot gives a m ore even weighting of points and 
is clearly non-linear. It could be described by two enzyme 
activities, an alleged type I (— ) and type II (...) 5<x-reductase 
isozyme. The abscissa intercepts o f these lines give the re ­
spective VmaxSj while the slopes indicate ~Km" 1 values of the 
isozymes. Both the x-values and  y-values are given as
m e a n i  S.D. of three duplicate assays.
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Fig. 3. 5a-Reductase type I and type II isozyme activity in 
human BPH tissue homogenates at pH 7.0 as described by the 
Vmax (black bars) or Vma)i/Km ratio (shaded bars). The specific 
activities, Vmax, indicate a quite different isozyme compo­
sition in this tissue than does the efficiency ratio Vma*/Km.
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higher T  concentrations (100-1000 nM), the pH opti­
mum was found at 5.5. At the lowest T  concentration 
tested (10 nM), however, the optimum was at pH 6 .0 . 
Thus j the pH-optimum strongly depends on the sub­
strate concentration chosen. As the affinity constant for 
5a-reductase activity depends substantially on pH 
[19, 27], the pH-optimum found will greatly influence 
reported K m values for 5a-reductase in BPH tissue. 
This might—in part—explain the wide range of K ms 
reported for 5a-reductase activities [26]. We decided to 
measure enzyme activities at pH 7.0, as this is probably 
the physiological pH for both isozymes [19].
The existence of type II 5a-reductase in human 
prostatic tissue is now well accepted [9-13]. In patients 
with a type II 5a-reductase deficiency (male pseudo­
hermaphroditism) the prostate is atrophic [14,15]. In 
these patients the type I isozyme is unaffected, indicat­
ing the crucial function of the type II isozyme in the 
development of the human prostate. Data concerning 
type I 5a -reductase diverge, as some authors deny the 
existence of the type I isozyme in the human prostate 
[10,12], whereas others claim its presence [9, 13]. 
Preliminary data has been published reporting equal 
amounts of type I and type II activity in human 
prostatic tissue [18]. We describe here the presence of 
two isozymes in a full homogenate of BPH tissue, by 
applying high T concentrations and by using an 
Eadie-S cat chard plot of the obtained data. This plot is 
particularly suitable for identifying two isozymes as it 
leads to a more even weighting of points as compared 
to the Line weaver—Burk plot [21]. The affinity con­
stants for these isozymes are typical for the type I and
II 5a-reductase subtypes at neutral pH as reported in 
literature [16, 19, 27]. When V mAX is taken as a measure 
of enzyme concentration, our results imply that there 
is an approx. 6-fold higher amount of type I 5a- 
reductase than of type II at pH 7.0 in the human 
hyperplastic prostate. However, one has to be cautious 
regarding these results; to preserve all cellular com­
ponents we did not centrifuge our homogenate, but 
filtered the preparation through nylon netting which 
might have led to a preferential recovery of epithelial 
components [7]. Stroma and epithelium do probably 
not exhibit the same 5a-reductase isozyme composition 
[5-8]. Thus a better recovery for the epithelial com­
ponents in this study would have led to a difference in 
relative isozyme concentrations found. Furthermore, 
unlike this paper, most studies use a centrifugation step 
in their experimental procedure to remove cell debris. 
However, whole nuclei will also be lost at 800 g> and as 
there might be a difference in intracellular localization 
between both 5a-reductase subtypes, more of a nuclear 
bound isozyme could have been detected with our 
protocol than in these other studies.
For enzyme quantification several definitions can be 
used: the maximum velocity at the optimum pH of the 
isozyme, the V max at neutral pH—as the acidic pH 
optimum of the type II 5a-reductase is probably not
physiological—or the efficiency ratio as a
measure of isozyme activity, instead of isozyme concen­
tration. All these definitions can, and have been, used. 
At pH 5,5 a maximum velocity of 0.7 pmol/(min-mg 
protein) was founds at pH 7.0 the Fmax was 
0.13 pmol/(min-mg protein), indicating a 5.4-fold 
higher type II than type I isozyme specific activity 
(results not shown). Considering our data of isozyme 
activity at pH 7.0, the Kraax of the type I isozyme 
appeared to be 6.2 times higher than that of the type
II. However., the V m&J K m ratios for both isozymes 
point to a 26.9-fold higher potential in v ivo  activity for 
the type II than the type I isozyme in human prostatic 
tissue at pH 7,0. When this efficiency ratio is used as 
a measure of isozyme activity, the results suggest that 
a specific type II isozyme inhibitor, like finasteride, 
should suffice in decreasing prostatic D H T  tissue levels 
in the clinical management of BPH. However, it has not 
been unequivocally ascertained whether the premise of 
K m »  [S] for the use of the efficiency ratio is valid in the 
microenvironment of the type I isozyme; human pro­
static 5a-reductase is reported to be located in the 
nucleus [28], One can speculate that the type I isozyme 
could be active when T  is accumulated in the nucleus 
to a higher substrate concentration, e.g. by binding to 
the androgen receptor. If this would be the case, the 
substantial type I 5a-reductase activity reported here 
might call for an evaluation of a combination therapy 
with type I and II isozyme inhibitors for BPH [15]. 
Experiments are underway in our laboratory to ascer­
tain the intracellular localization of both isozymes and 
to check the validity of the V maJ K m ratio. The dis­
crepancies in isozyme specific mRNA, immunoreactiv- 
ity and activity measurements in the human prostate 
might be attributable to differences in translation from 
mRNA to protein, or to differences in catalytic 
efficiency from protein to activity between the two 
isozymes.
In conclusion, we present here evidence for the 
presence of a substantial amount of type I 5a-reductase 
in human benign prostatic hyperplastic tissue hom­
ogenates in addition to the well established type II. 
Nevertheless, although type I has an approx. 6-fold 
higher specific activity than type II 5a-reductase at 
neutral pH, it is most probably the type II isozyme that 
is quantitatively responsible for the formation of D H T  
in the human prostrate, considering the efficiency ratio 
V maJ K m of the isozymes in this tissue. However, the 
intracellular and cell-type specific localization of both 
isozymes has to be considered so as to shed more light 
on the possible physiological roles of both isozymes in 
this tissue. The role of the reported prostatic type I 
5a-reductase isozyme in BPH remains intriguing.
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